In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) closed at $0.46 in the last session, down -3.66% from day before closing price of $0.48. In other words, the price has decreased by -$3.66 from its previous closing price. On the day, 0.59 million shares were traded. IPA stock price reached its highest trading level at $0.48 during the session, while it also had its lowest trading level at $0.45.
Ratios:
We take a closer look at IPA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.85 and its Current Ratio is at 1.01. In the meantime, Its Debt-to-Equity ratio is 0.50 whereas as Long-Term Debt/Eq ratio is at 0.36.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 02, 2022, initiated with a Buy rating and assigned the stock a target price of $9.
On October 25, 2021, The Benchmark Company started tracking the stock assigning a Buy rating and target price of $12.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IPA now has a Market Capitalization of 21102288 and an Enterprise Value of 23900370. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.19 while its Price-to-Book (P/B) ratio in mrq is 0.60. Its current Enterprise Value per Revenue stands at 0.992 whereas that against EBITDA is -2.077.
Stock Price History:
The Beta on a monthly basis for IPA is 0.34, which has changed by -0.7518135 over the last 52 weeks, in comparison to a change of 0.21313763 over the same period for the S&P500. Over the past 52 weeks, IPA has reached a high of $2.43, while it has fallen to a 52-week low of $0.32. The 50-Day Moving Average of the stock is 0.31%, while the 200-Day Moving Average is calculated to be -36.53%.
Shares Statistics:
According to the various share statistics, IPA traded on average about 6.20M shares per day over the past 3-months and 1155300 shares per day over the past 10 days. A total of 30.29M shares are outstanding, with a floating share count of 20.05M. Insiders hold about 19.60% of the company’s shares, while institutions hold 7.72% stake in the company. Shares short for IPA as of 1731628800 were 688805 with a Short Ratio of 0.01, compared to 1728950400 on 146079. Therefore, it implies a Short% of Shares Outstanding of 688805 and a Short% of Float of 2.41.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
According to 2 analysts, the current quarter’s revenue is expected to be $6.58M. It ranges from a high estimate of $6.97M to a low estimate of $6.2M. As of the current estimate, ImmunoPrecise Antibodies Ltd’s year-ago sales were $6.22MFor the next quarter, 2 analysts are estimating revenue of $6.77M. There is a high estimate of $7.09M for the next quarter, whereas the lowest estimate is $6.45M.
A total of 2 analysts have provided revenue estimates for IPA’s current fiscal year. The highest revenue estimate was $25.45M, while the lowest revenue estimate was $24.04M, resulting in an average revenue estimate of $24.74M. In the same quarter a year ago, actual revenue was $24.52MBased on 1 analysts’ estimates, the company’s revenue will be $27.18M in the next fiscal year. The high estimate is $27.18M and the low estimate is $27.18M.
